Could a common diabetes drug stop oral cancer before it starts?
NCT ID NCT02581137
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether metformin, a widely used diabetes drug, can prevent oral cancer in 26 people with precancerous mouth lesions (leukoplakia or erythroplakia). Participants take metformin by mouth, and researchers check if the lesions shrink or disappear. The goal is to see if this safe, affordable drug can stop cancer from forming.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin (a common diabetes drug)
What this could lead to
If it works, this could point toward a way to prevent oral cancer in people with precancerous mouth lesions.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply to everyone. Metformin is generally safe but can cause side effects like stomach upset.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPLAKIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Research Centre
Vancouver, British Columbia, V5Z 1L3, Canada
-
UC San Diego Medical Center - Hillcrest
San Diego, California, 92103, United States
-
University of British Columbia Hospital
Vancouver, British Columbia, V6T 2B5, Canada
-
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States